The closing price of Cara Therapeutics Inc (NASDAQ: CARA) was $0.89 for the day, down -5.87% from the previous closing price of $0.95. In other words, the price has decreased by -$0.0555 from its previous closing price. On the day, 775311 shares were traded.
Ratios:
Our analysis of CARA’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 4.25 and its Current Ratio is at 4.40. In the meantime, Its Debt-to-Equity ratio is 0.09 whereas as Long-Term Debt/Eq ratio is at 0.08.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, BofA Securities on March 08, 2023, Downgraded its rating to Underperform and sets its target price to $6 from $13 previously.
On March 08, 2022, JP Morgan Upgraded its rating to Overweight which previously was Neutral and also upped its target price recommendation from $17 to $20.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Feb 08 when Posner Christopher sold 35,575 shares for $0.53 per share. The transaction valued at 18,855 led to the insider holds 186,355 shares of the business.
Posner Christopher sold 4,981 shares of CARA for $2,740 on Feb 01. The PRESIDENT AND CEO now owns 221,930 shares after completing the transaction at $0.55 per share. On Nov 02, another insider, Posner Christopher, who serves as the President and CEO of the company, sold 3,796 shares for $1.22 each. As a result, the insider received 4,631 and left with 164,411 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CARA now has a Market Capitalization of 48.49M and an Enterprise Value of -22.74M. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.28 while its Price-to-Book (P/B) ratio in mrq is 0.57. Its current Enterprise Value per Revenue stands at -1.07 whereas that against EBITDA is 0.19.
Stock Price History:
The Beta on a monthly basis for CARA is 0.72, which has changed by -90.35% over the last 52 weeks, in comparison to a change of 27.55% over the same period for the S&P500. Over the past 52 weeks, CARA has reached a high of $10.39, while it has fallen to a 52-week low of $0.50. The 50-Day Moving Average of the stock is 0.6514, while the 200-Day Moving Average is calculated to be 1.9085.
Shares Statistics:
CARA traded an average of 897.57K shares per day over the past three months and 1.13M shares per day over the past ten days. A total of 53.80M shares are outstanding, with a floating share count of 46.25M. Insiders hold about 15.11% of the company’s shares, while institutions hold 46.99% stake in the company. Shares short for CARA as of Feb 15, 2024 were 2.23M with a Short Ratio of 2.49, compared to 2.38M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 4.10% and a Short% of Float of 5.72%.
Earnings Estimates
The firm’s stock currently is rated by 5 analysts. On average, analysts expect EPS of -$0.41 for the current quarter, with a high estimate of $0.19 and a low estimate of -$0.6, while EPS last year was -$0.56. The consensus estimate for the next quarter is -$0.42, with high estimates of -$0.33 and low estimates of -$0.53.
Analysts are recommending an EPS of between -$1.4 and -$2.19 for the fiscal current year, implying an average EPS of -$2.01. EPS for the following year is -$1.26, with 4 analysts recommending between -$1.09 and -$1.5.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 5 analysts. It ranges from a high estimate of $37.7M to a low estimate of $1.09M. As of the current estimate, Cara Therapeutics Inc’s year-ago sales were $3.26M, an estimated increase of 188.90% from the year-ago figure. For the next quarter, 5 analysts are estimating revenue of $2.26M, a decrease of -63.30% less than the figure of $188.90% in the same quarter last year. There is a high estimate of $2.8M for the next quarter, whereas the lowest estimate is $1.23M.
A total of 5 analysts have provided revenue estimates for CARA’s current fiscal year. The highest revenue estimate was $55.7M, while the lowest revenue estimate was $19.06M, resulting in an average revenue estimate of $27.41M. In the same quarter a year ago, actual revenue was $41.87M, down -34.50% from the average estimate. Based on 5 analysts’ estimates, the company’s revenue will be $5.54M in the next fiscal year. The high estimate is $9.44M and the low estimate is $1.98M. The average revenue growth estimate for next year is down -79.80% from the average revenue estimate for this year.
